Inari Medical to Announce First Quarter 2021 Financial Results
Inari Medical (NASDAQ: NARI) announced its financial results for Q1 2021 will be released on May 11, 2021. A conference call and webcast will occur the same day at 1:30 PM PT / 4:30 PM ET to discuss the results and recent highlights. Inari is a commercial-stage medical device company focused on innovative treatments for venous diseases. Its key products include the ClotTriever and FlowTriever systems, both FDA cleared and CE Mark approved for treating deep vein thrombosis and pulmonary embolism.
- Innovative product offerings with FDA and CE Mark approvals for treating venous diseases.
- Scheduled financial results release and conference call may indicate transparent communication with investors.
- None.
IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its financial results for the first quarter of 2021 on Tuesday, May 11, 2021. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (833)-519-1265 for domestic callers or (914)-800-3838 for international callers, using conference ID: 5787033. The live webinar of the call may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.
About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
FAQ
When will Inari Medical release its Q1 2021 financial results?
What time is Inari Medical's conference call for financial results?
What products does Inari Medical offer for venous diseases?
Is Inari Medical's ClotTriever system FDA-approved?
